| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.
For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.
In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.
Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.
Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.
Alzheimer's disease is the most common form of dementia and affecting about 6 million people in the United States. A simple blood test is providing a new way for doctors to detect the potential risk of Alzheimer's disease in its early stages. Here to talk about this groundbreaking new approach is a board-certified neurologist and medical director of neurology at Quest Diagnostics.
Diagnostics firm Diadem said Wednesday that it has licensed exclusive US rights to its AlzoSure Predict Alzheimer's blood test to Quest Diagnostics. Under the agreement, Quest can develop, validate, and market the assay, which is intended to identify individuals likely to progress to Alzheimer's disease, as a laboratory-developed test in the US. AlzoSure Predict measures a variant of the p53 protein that has been linked to Alzheimer's disease.
Laboratory operator Quest Diagnostics on Tuesday raised its full-year sales forecast after beating third-quarter expectations for revenue and profit, buoyed by a recovery in routine testing. The company raised its full-year net sales forecast to $9.19 billion to $9.24 billion, from its previous expectations of $9.12 billion to $9.22 billion. Sales from Quest's base business, which includes a range of diagnostic tests for allergies, chronic diseases and cancer, rose 4.6% to $2.27 billion in the third quarter. That extends a rebound in routine health check-ups delayed due to pandemic-related lockdowns for diagnostic firms like Quest and eases the blow from plunging demand for COVID-19 tests.
Dialysis company Neway said Thursday that it has entered a strategic lab services arrangement with Quest Diagnostics to speed dialysis lab testing and reduce testing costs for patients with end-stage renal disease (ESRD). Under the terms of the agreement, Neway will use Quest's lab network to provide local testing services, enabling next-day results while also reducing sample transportation costs.
Self-service has seen incredible growth in recent years, and this is just the beginning. 81% of customers want more self-service options. Here are 20 of the best examples of self-service:
13. Quest Diagnostics Cuts Wait Time with Kiosks
Medical lab company Quest Diagnostics cuts wait times with interactive kiosks that patients can use to check in, upload insurance information, and make payments. The devices help patients be seen faster, allowing medical staff to spend more time working with patients and less on administrative tasks.
Stamford-based Americares is partnering with Quest Diagnostics to provide 10 clinics across the U.S. with no-cost diagnostic services for one year as a means of increasing access to care for low-income, uninsured and underinsured patients.
Rutgers and Quest Diagnostics are expanding their collaboration to further improve access to critical primary care services for uninsured patients of the university’s Health Outreach Practice Experience (H.O.P.E.) Clinic in Plainfield. Resources from the Quest Diagnostics Foundation will enable the clinic to double its capacity by providing primary care services for a second day of the week.
Quest Diagnostics has secured breakthrough device designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay, from the US Food and Drug Administration (FDA). The test is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in the serum of humans. Quest also expanded collaboration with Sarepta to develop complementary diagnostics for Sarepta's gene therapies.
Researchers from Quest Diagnostics and collaborators have found that changes in levels of the cardiovascular risk marker free myeloperoxidase (MPO) appear correlated with an individual's overall mortality risk. The finding, described in a study published last month in PLOS One, indicate that longitudinal measurement of MPO could help physicians assess patients' mortality risk and response to interventions.
Quest Diagnostics has partnered with Envision Sciences to commercially launch a novel prostate cancer biomarker test to help in identifying patients with more aggressive forms of the disease, Quest Diagnostics and the University of South Australia announced in separate news releases.1,2"Our goal for this innovative prostate biomarker test is to improve the accuracy of grading prostate cancer biopsies.
Made by New Jersey–based Quest Diagnostics, the $399 test can be purchased online by anyone age 18 and older in most US states, who then must go to a Quest clinic for a blood draw. The test measures blood levels of a protein called amyloid beta. As a person ages, amyloid beta tends to accumulate in the brain and can eventually form plaques, which are linked to Alzheimer’s disease. It’s thought that these clumps build up many years before memory loss and confusion appear.
For decades, employers have relied on workplace drug testing as a risk mitigation tool to effectively deter drug use and help prevent costly incidents. However, with cannabis legalization expanding, so is its use and acceptance. The connection between increasing cannabis availability and increased use of cannabis at work creates significant risks and costs for employers. So, why isn’t it possible to determine impairment from cannabis yet? “The main point many people fail to realize is that alcohol had decades, literally decades, of study to get to an impairment standard,” toxicology and workforce drug testing expert Barry Sample, of Quest Diagnostics, explains.
Quest Diagnostics launched on July 31 a direct-to-consumer blood test to detect abnormal levels of beta-amyloidTrusted Source, a protein involved in Alzheimer’s disease that can show up in the brain years before symptoms arise. The first-of-its-kind test, called AD-Detect, will cost $399, plus a $13 physician service fee. The technology is the same as the AD-Detect Amyloid Beta 42/40 Ratio blood test launched by the company in early 2022, which is available with a doctor’s order.
Laboratory operator Quest Diagnostics Inc beat estimates for quarterly profit on Wednesday, as people returned for regular checkups and tests that were delayed during a large part of the COVID-19 pandemic. Non-COVID testing at companies such as Quest and rival Labcorp was hit as people delayed routine health check-ups following pandemic-led lockdowns, but that demand has now started to normalize while COVID testing sales have fallen.
An analysis of 462 million lipid test results has shown mean total cholesterol levels exceed the target in seven of the 17 studied countries. Writing in the European Heart Journal, members of the Global Diagnostics Network (GDN) describe the evaluation of lipid test data generated by nine clinical laboratories working in 17 countries. Seth Martin, lead author of the study and professor of medicine at Johns Hopkins University School of Medicine, discussed the analysis and the potential implications of its findings in a statement from Quest Diagnostics, the company that leads the GDN.
Quest Diagnostics said Thursday that women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com. The Proov Confirm PdG test is the first and only FDA-cleared PdG (progesterone metabolite) home test kit to confirm successful ovulation. Through a collaboration between Secaucus-based Quest and Proov, the test is the first women’s health test from a third-party manufacturer available through questhealth.com.
For a decade now, the world has had highly effective medications for hepatitis C infections. In the United States, they’ve mostly been sitting on the shelf, according to a new study. A study published Thursday in the CDC’s Morbidity and Mortality Weekly Report reveals how deep the disparities in access to hepatitis C therapies have become. Using testing data from Quest Diagnostics, researchers were able to track the fates of 1 million Americans diagnosed with hepatitis C infections in the decade since the most effective drugs were introduced. Overall, just 1 in 3 were cured over that time period.
Quest Diagnostics has finalized its previously announced acquisition of Baltimore-based Haystack Oncology, the Secaucus clinical laboratory company said June 21. Under the terms of the deal unveiled April 27, Quest said it would pay Haystack $300 million in cash at closing, net of cash acquired, and up to an additional $150 million based on future performance milestones.
The ongoing flurry of marijuana legislation, court cases and cannabis-based products makes it difficult for HR professionals to craft policies that meet their company's drug-testing needs. The significant differences in state-by-state rules, definitions and interpretations of recreational and medical marijuana products have only added to the potential confusion. People in U.S. states that legalized recreational cannabis use it 20 percent more frequently than people in other states, according to a 2022 study in the journal Addiction. Nationwide, 4.4 percent of workers failed tests that Quest Diagnostics processed in 2020, up from 3.5 percent in 2012. The rate was slightly higher in states where adults are allowed to buy recreational marijuana.
Alzheimer’s disease is devastating to both patients and their families and caregivers. And while there are better means to diagnosis Alzheimer’s today, in many cases, it is only determined after symptoms become apparent. Today, about 6 million Americans are struggling with Alzheimer’s disease and other dementias. That number is expected to more than double by mid-century. In a wide-ranging discussion about the disease with CLP, Michael Racke, MD, medical director of neurology for Quest Diagnostics, outlines a new test that can help spot Alzheimer’s and other dementias earlier, what that means for treatment options, and how it could help transform Alzheimer’s into a manageable condition and not a death sentence for patients.